Kowa Company Limited

Akio Iwasaki

Toshihito Mori

Takeo Deushi

Toshimi Mizoguchi

Masahito Nakayama

Kazuhiro Kamiya

Hisakatsu Ito

Isamu Watanabe

Shigeru Kimura

Yushi Saino

Takeshi Oda

Takafumi Kunieda

Takeshi Doi

Masao Ohkuchi

Makoto Suda

Sohei Tanabe

Hisakatsu Itoh

Akira Murakami

Masao Okuchi

Naoki Harada

Yasushi Saito

Kazuhiro Takagi

Hiroyuki Yamazaki

Koichi Arai

Masahoto Nakayama

Kunihiko Fujii

Disclosed are: a novel microorganism which can decompose a methylthiotriazine compound (particularly, simetryn, dimethametryn, prometryn), a chlorotriazine compound (particularly, simazine, atrazine, propazine) and a methoxytriazine compound (particularly, simeton, atraton, prometon) which have been frequently used as agrichemicals or the like; and a method for decomposing a methylthiotriazine compound, a chlorotriazine compound and/or a methoxytriazine compound by using the microorganism. Specifically disclosed are: a novel bacteriumsp. strain MTD22 which is capable of decomposing a methylthiotriazine compound, a chlorotriazine compound and a methoxytriazine compound; and a method for decomposing a methylthiotriazine compound, a chlorotriazine compound and/or a methoxytriazine compound, particularly simetryn, dimethametryn, prometryn, simazine, atrazine, propazine, simeton, atraton and/or prometon, by using the microorganism.

Microorganism capable of microbially decomposing chloro-, methylthio- and methoxy-triazine agrichemicals

The present invention is drawn to a DNA encoding a novel LDL receptor-analog. LDL receptors participate in lipoprotein metabolism, which is a critical factor in the onset of arteriosclerosis. The invention provides DNA having the nucleotide sequences shown by SEQ ID NOS: 1 and 5, which encode rabbit and human LDL receptor analog proteins having the sequences shown in SEQ ID NOS: 3 and 7 respectively.

LDL receptor analog protein and DNA coding therefor

A polypeptide having a specific amino acid sequence is described. Also described are a novel DNA coding the polypeptide, a recombinant plasmid containing the DNA, a transformant containing the recombinant plasmid, an anticoagulant containing the polypeptide as an effective ingredient, and a process for the production of the polypeptide.

Nucleic acids encoding human placental coagulation inhibitor (PCI)

Thrombin-binding substances capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively on a large scale.

DNA encoding a human thrombomodulin having a modified glycosaminoglycan

Recombinant thrombin-binding substances, derived from thrombomodulin by modification of the c-terminal glycosaminoglycan (GAG) binding site and capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively in a large scale.

Human urinary thrombomodulin with a modified glycosaminoglycan (GAG)

A polypeptide having an amino acid sequence as shown in FIG. 1 and its preparation method are disclosed. A DNA fragment capable of coding CPBII polypeptide (human placenta-derived coagulation inhibitor) is first obtained from the human placental cDNA library by using a CPBII-specific antibody as a probe. Then, microorganism cells are transformed by the use of a recombinant plasmid incorporated with the DNA fragment, allowing the resultant transformant to express the CPBII gene, to finally obtain a CPBII-like polypeptide. The polypeptide of this invention exhibits strong anticoagulation activities, and useful for an active component of anticoagulation medicines and preventin in vivo blood coagulation.

Method of treatment using an anticoagulant polypeptide

A novel antibiotic designated as KA-6643 and having the formula, ##STR1## wherein R is hydrogen or --SO.sub.3 H.

.beta.-Lactam antibiotics

A process for producing an antibiotic, which comprises cultivating an antibiotic KA-6606-producing strain of the genus Saccharopolyspora in a nutrient culture medium, isolating an antibiotic KA-6606-containing substance from the culture broth, and separating from the resulting antibiotic KA-6606-containing substance at least one antibiotic selected from the group consisting of antibiotic KA-6606 VII, KA-6606 VIII, KA-6606 IX, KA-6606 X, KA-6606 XI, KA-6606 XII, KA-6606 XIII, KA-6606 XIV, KA-6606 XV, KA-6606 XVI and KA-6606 XVII; and novel antibiotics KA-6606 XII, XIII and XV to XVII.

Antibiotics KA-6606 XII, XIII, XV, XVI and XVII

A-KA-6643-series antibiotic comprising at least one substance represented by any of the following formulae, or a salt or ester thereof: ##STR1## is effectively useful as an antibacterial and .beta.-lactamase inhibiting agent.

KA-6643-Series antibiotics, process for producing same and medical

A process for producing an antibiotic, which comprises cultivating an antibiotic KA-6606-producing strain of an genus Saccharopolyspora in a nutrient culture medium, isolating the antibiotic KA-6606-containing substance from the culture broth, and separating from the resulting antibiotic KA-6606-containing substance at least one antibiotic selected from the group consisting of antibiotic KA-6606 VII, KA-6606 VIII, KA-6606 IX, KIA-6606 X, KA-6606 XI, KA-6606 XII, KA-6606 XIII, KA-6606 XIV, KA-6606 XV, KIA-6606 XVI and KA-6606 XVII; and novel antibiotics KA-6606 XII, XIII and XV to XVII.

Process for production of antibiotics and novel antibiotics produced

Novel antibiotics of the following structure ##STR1## wherein R represents a moiety selected from the group consisting of hydrogen, --COCH.sub.2 NH.sub.2, --COCH.sub.2 NHCONH.sub.2 and --COCH.sub.2 NHCHO; process for preparation thereof; and biologically pure culture for use therein.

Biologically pure culture

An antibiotic substance KA-7038 selected from the group consisting of the compounds having formulae I to VII described in claim 1, mixtures thereof and acid addition salts thereof; an antibiotic composition composed of (i) antibiotically effective amount of aforesaid antibiotic substance KA-7038, and (ii) a pharmaceutically acceptable diluent or carrier. The antibiotic substance KA-7038 can be produced by cultivating an antibiotic substance KA-7038-producing strain belonging to genus Streptomyces, for example Streptomyces sp. KC-7038, and isolating the antibiotic substance KA-7038 from the culture broth.

Process for preparation of antibiotics and biologically pure culture for

Novel antibiotics, process for preparation thereof and biologically pure

Antibiotic KA-7038 and compositions containing same

Novel aminoglycosides of the following formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different and each represents a hydrogen atom or a methyl group, R.sub.3 represents a hydrogen atom or an optionally substituted aminoacyl group having 2 to 4 carbon atoms in the acyl moiety, and when all of R.sub.1, R.sub.2 and R.sub.3 are hydrogen atoms, the methylamino group at the 4-position is not oriented trans to the hydroxyl groups at the 3- and 5-positions; and acid addition salts thereof, which are useful as antibiotics; and process for producing compounds containing the same.

Growing community of inventors

Higashimurayama, Japan

Akio Iwasaki